- Gravis" (Press release).
Argenx. 17
December 2021.
Archived from the
original on 20
December 2021.
Retrieved 21
December 2021. "
Argenx Announces U.S. Food...
- "
Argenx Announces U.S. Food and Drug
Administration (FDA)
Approval of
Vyvgart (efgartigimod alfa-fcab) in
Generalized Myasthenia Gravis".
Argenx (Press...
- DailyMed. 21 June 2023.
Retrieved 29
August 2023. "Halozyme
Announces argenx Receives FDA
Approval for
Vyvgart Hytrulo With
Enhanze for Subcutaneous...
- text from this source,
which is in the
public domain. "Halozyme
Announces argenx Receives FDA
Approval for
Vyvgart Hytrulo With
Enhanze for Subcutaneous...
- cancers. In the same
month the
company announced it
would co-commercialize
Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy...
-
includes holdings in
Ionis Pharmaceuticals, Moderna,
Neurocrine Biosciences,
Argenx, Incyte,
Vertex Pharmaceuticals,
Alexion Pharmaceuticals, Arvinas, Fate...
-
Vulgaris therapeutics include Principia Biopharma,
Topas Therapeutics and
Argenx BVBA.[citation needed]
Rituximab demonstrated superior efficacy compared...
- 2022). "AAN:
AstraZeneca touts new
Ultomiris gMG data
ahead of
potential Argenx showdown".
Fierce Pharma.
Archived from the
original on 9
April 2022. Retrieved...
- "
argenx Announces U.S. Food and Drug
Administration (FDA)
Approval of VYVGART™ (efgartigimod alfa-fcab) in
Generalized Myasthenia Gravis".
Argenx. 17...
-
AkzoNobel Amsterdam Alstom Paris Altice Paris ArcelorMittal Amsterdam,
Paris Argenx Brussels Arkema Paris ASM
International Amsterdam ASML
Amsterdam AXA Paris...
